MMJ International Holdings is developing an oral drug product from natural whole plant extract derivatives from the marijuana plant containing THC and CBD. MMJ will be utilizing its new product for a FDA approved treatment for multiple sclerosis (MS) and Huntington's disease (HD). It also received the US Drug Enforcement Agency's approval to ship the compounds for its clinical trials.

"As MMJ International Holdings continues to advance to its clinical trials, a specialty pharmaceutical solutions company will be supporting MMJ with the FDA, DEA required development API and specialized liquid encapsulation solutions," said Elio Mariani, PhD, EVP of research & development. "Patients will benefit from cGMP-quality therapies in an accessible and efficient format."